請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17463
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄧哲明(Che-Ming Teng) | |
dc.contributor.author | Chia-Hua Lee | en |
dc.contributor.author | 李嘉華 | zh_TW |
dc.date.accessioned | 2021-06-08T00:14:34Z | - |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-07-31 | |
dc.identifier.citation | Aka, J. A., G. W. Kim, et al. (2011). 'K-acetylation and its enzymes: overview and new developments.' Handb Exp Pharmacol 206: 1-12.
Bellucci, L., M. Dalvai, et al. (2013). 'Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z.' PLoS One 8(1): e54102. Boldin, M. P., T. M. Goncharov, et al. (1996). 'Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death.' Cell 85(6): 803-815. Bradley, E. W., M. E. McGee-Lawrence, et al. (2011). 'Hdac-mediated control of endochondral and intramembranous ossification.' Crit Rev Eukaryot Gene Expr 21(2): 101-113. CDC, C. f. D. C. a. P. (2013). 'Respiratory syncytial virus activity--United States, July 2011-January 2013.' MMWR Morb Mortal Wkly Rep 62(8): 141-144. Centelles, J. J. (2012). 'General aspects of colorectal cancer.' ISRN Oncol 2012: 139268. Chang, F., J. T. Lee, et al. (2003). 'Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.' Leukemia 17(3): 590-603. Chen, T. H., S. L. Pan, et al. (2008). 'Denbinobin induces apoptosis by apoptosis-inducing factor releasing and DNA damage in human colorectal cancer HCT-116 cells.' Naunyn Schmiedebergs Arch Pharmacol 378(5): 447-457. Cunningham, D., W. Atkin, et al. (2010). 'Colorectal cancer.' Lancet 375(9719): 1030-1047. Curtin, J. C. and M. V. Lorenzi (2010). 'Drug discovery approaches to target Wnt signaling in cancer stem cells.' Oncotarget 1(7): 563-577. D'Amelio, M., V. Cavallucci, et al. (2010). 'Neuronal caspase-3 signaling: not only cell death.' Cell Death Differ 17(7): 1104-1114. Davies, R. J., R. Miller, et al. (2005). 'Colorectal cancer screening: prospects for molecular stool analysis.' Nat Rev Cancer 5(3): 199-209. Dewson, G. and R. M. Kluck (2009). 'Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis.' J Cell Sci 122(Pt 16): 2801-2808. Duncan, H. F., A. J. Smith, et al. (2011). 'HDACi: cellular effects, opportunities for restorative dentistry.' J Dent Res 90(12): 1377-1388. Fearon, E. R. and B. Vogelstein (1990). 'A genetic model for colorectal tumorigenesis.' Cell 61(5): 759-767. Garber, K. (2009). 'Drugging the Wnt pathway: problems and progress.' J Natl Cancer Inst 101(8): 548-550. Gronbaek, K., C. Hother, et al. (2007). 'Epigenetic changes in cancer.' APMIS 115(10): 1039-1059. Guan, P., F. Sun, et al. (2012). 'Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.' Bioorg Med Chem 20(12): 3865-3872. Hanahan, D. and R. A. Weinberg (2011). 'Hallmarks of cancer: the next generation.' Cell 144(5): 646-674. Jemal, A., F. Bray, et al. (2011). 'Global cancer statistics.' CA Cancer J Clin 61(2): 69-90. Jiang, X., Y. Wang, et al. (2013). '[Typical symptoms of colorectal cancer and its influence in timely diagnosis].' Zhonghua Yi Xue Za Zhi 93(4): 275-279. Jiang, Y. H., J. Bressler, et al. (2004). 'Epigenetics and human disease.' Annu Rev Genomics Hum Genet 5: 479-510. Jones, P. A. and S. B. Baylin (2007). 'The epigenomics of cancer.' Cell 128(4): 683-692. Kerr, E., C. Holohan, et al. (2012). 'Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis.' Cell Death Differ 19(8): 1317-1327. Khan, O. and N. B. La Thangue (2012). 'HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.' Immunol Cell Biol 90(1): 85-94. Koros, E. and C. Dorner-Ciossek (2007). 'The role of glycogen synthase kinase-3beta in schizophrenia.' Drug News Perspect 20(7): 437-445. Lawen, A. (2003). 'Apoptosis-an introduction.' Bioessays 25(9): 888-896. Leslie, A., N. R. Pratt, et al. (2003). 'Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas.' Cancer Res 63(15): 4656-4661. Li, H., H. Zhu, et al. (1998). 'Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.' Cell 94(4): 491-501. Li, J. and J. Yuan (2008). 'Caspases in apoptosis and beyond.' Oncogene 27(48): 6194-6206. Lieberman, D. A. (2009). 'Clinical practice. Screening for colorectal cancer.' N Engl J Med 361(12): 1179-1187. Luo, X., I. Budihardjo, et al. (1998). 'Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.' Cell 94(4): 481-490. Ma, X., H. H. Ezzeldin, et al. (2009). 'Histone deacetylase inhibitors: current status and overview of recent clinical trials.' Drugs 69(14): 1911-1934. MacKenzie, S. H. and A. C. Clark (2012). 'Death by caspase dimerization.' Adv Exp Med Biol 747: 55-73. Mariadason, J. M. (2008). 'HDACs and HDAC inhibitors in colon cancer.' Epigenetics 3(1): 28-37. Martinet, N. and P. Bertrand (2011). 'Interpreting clinical assays for histone deacetylase inhibitors.' Cancer Manag Res 3: 117-141. Pinton, G., A. G. Manente, et al. (2012). 'Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma.' PLoS One 7(5): e36856. Portela, A. and M. Esteller (2010). 'Epigenetic modifications and human disease.' Nat Biotechnol 28(10): 1057-1068. Qiu, L., A. Burgess, et al. (2000). 'Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.' Mol Biol Cell 11(6): 2069-2083. Rangwala, S., C. Zhang, et al. (2012). 'HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.' Future Med Chem 4(4): 471-486. Rastogi, R. P., Richa, et al. (2009). 'Apoptosis: Molecular Mechanisms and Pathogenicity.' Excli Journal 8: 155-181. Rikiishi, H. (2011). 'Autophagic and apoptotic effects of HDAC inhibitors on cancer cells.' J Biomed Biotechnol 2011: 830260. Schroeder, T. M. and J. J. Westendorf (2005). 'Histone deacetylase inhibitors promote osteoblast maturation.' J Bone Miner Res 20(12): 2254-2263. Siegel, R., D. Naishadham, et al. (2013). 'Cancer statistics, 2013.' CA Cancer J Clin 63(1): 11-30. Smith, M. R., F. Jin, et al. (2007). 'Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.' Clin Cancer Res 13(18 Pt 2): 5528s-5534s. Song, S. H., S. W. Han, et al. (2011). 'Epigenetic-based therapies in cancer: progress to date.' Drugs 71(18): 2391-2403. Spiegel, S., S. Milstien, et al. (2012). 'Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.' Oncogene 31(5): 537-551. Tanaka, S., M. Terasaki, et al. (2013). 'Warning for unprincipled colorectal endoscopic submucosal dissection: accurate diagnosis and reasonable treatment strategy.' Dig Endosc 25(2): 107-116. Thompson, R. C., I. Vardinogiannis, et al. (2013). 'The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein Activity.' PLoS One 8(5): e62822. Thorstensen, L., G. E. Lind, et al. (2005). 'Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability.' Neoplasia 7(2): 99-108. Tomlinson, I. P., M. R. Novelli, et al. (1996). 'The mutation rate and cancer.' Proc Natl Acad Sci U S A 93(25): 14800-14803. Venugopal, B. and T. R. Evans (2011). 'Developing histone deacetylase inhibitors as anti-cancer therapeutics.' Curr Med Chem 18(11): 1658-1671. Villanueva, A. and J. M. Llovet (2011). 'Targeted therapies for hepatocellular carcinoma.' Gastroenterology 140(5): 1410-1426. Waldner, M. J. and M. F. Neurath (2010). 'The molecular therapy of colorectal cancer.' Mol Aspects Med 31(2): 171-178. Weichert, W. (2009). 'HDAC expression and clinical prognosis in human malignancies.' Cancer Lett 280(2): 168-176. Wilson, A. J., D. S. Byun, et al. (2006). 'Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.' J Biol Chem 281(19): 13548-13558. Witt, O., H. E. Deubzer, et al. (2009). 'HDAC family: What are the cancer relevant targets?' Cancer Lett 277(1): 8-21. Wolpin, B. M. and R. J. Mayer (2008). 'Systemic treatment of colorectal cancer.' Gastroenterology 134(5): 1296-1310. Wu, Y. and B. P. Zhou (2010). 'TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion.' Br J Cancer 102(4): 639-644. Zhang, Y., J. Feng, et al. (2010). 'Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.' Bioorg Med Chem 18(5): 1761-1772. Zhu, P., E. Martin, et al. (2004). 'Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.' Cancer Cell 5(5): 455-463. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17463 | - |
dc.description.abstract | 癌症自民國72年以來已連續30年蟬聯國人十大死因之首,而近年來,隨著飲食西化及診斷儀器的精進,使大腸直腸癌的發生率持續攀升。大部分的病患以手術切除可以治癒,然而術後的復發則使其死亡率居高不下。
許多文獻證實,癌症常伴隨異常高度表現的histone deacetylases (HDACs),而這樣的現象被發現是跟epigenetic的改變有高度關聯性。所以針對HDAC做為標的而發展的HDAC抑制劑在癌症的治療上是具有相當潛力的。本篇論文中,探討一個新合成的HDAC抑制劑MPT0G028在大腸直腸癌細胞上的抗癌機轉。 首先,篩選一系列以tetrahydroquinoline為結構基底所設計出來的HDAC抑制劑,發現人類大腸直腸細胞癌HCT-116細胞對MPT0G028的抑制效果有最好的反應。根據所觀察到的實驗結果,MPT0G028比FDA所核准的pan-HDAC抑制劑SAHA具有更好的細胞抑制生長、細胞毒殺和HDAC抑制能力。藉由fluorogenic HDAC assay kit,觀察到MPT0G028對於class I HDAC的活性抑制較為明顯。MPT0G028在HCT-116可以增加組蛋白H3乙醯化和HDAC被抑制的指標p21WAF1/CIP1蛋白表現,然而α-tubulin的乙醯化程度不明顯。進一步的實驗結果顯示,MPT0G028調控HCT-116的細胞凋亡,包括Sub G1期的增加及caspase 3、PARP的切割現象;並且在內生性細胞凋亡路徑上,增加pro-apoptosis蛋白Bak、Bim,減少BID proform及減少anti-apoptosis蛋白Bcl-2、Bcl-xL、Mcl-1。另外,MPT0G028抑制β-catenin蛋白及其上游蛋白Akt、磷酸化GSK-3β,以及下游蛋白cyclin D1、c-Myc、survivin。最後,在腫瘤移植的動物模式中也發現,MPT0G028可有效抑制腫瘤體積,且其低毒性對於動物的體重影響不大。總結而言,MPT0G028在人類大腸直腸癌細胞中可有效的抑制HDAC活性、促進細胞凋亡,並且抑制β-catenin和其上、下游蛋白的表現。 關鍵詞:大腸直腸癌、HDAC抑制劑、細胞凋亡、β-catenin | zh_TW |
dc.description.abstract | Cancer has been the top of ten leading causes of death in Taiwan since 1982. In the decades, the incidence of colorectal cancer (CRC) has been increasing rapidly due to accompanying westernized diet and sophisticated diagnosis instruments. Although most patients are curable by surgery, recurrence of CRC is the main problem and cause of the high mortality rate.
It has been reported that cancer progression is related to overexpression of histone deacetylases (HDACs), and the phenomenon was highly accordant with epigenetic change. Therefore, development of drugs that target on HDACs could be a promising strategy for the treatment of cancer. In the current study, we investigated the anti-cancer activity of a novel HDAC inhibitor, MPT0G028, on colorectal cancer cell lines. First, MPT0G028 showed the best anti-proliferative effect among a series of tetraquinoline derivatives in HCT-116 cells. According to observed results, MPT0G028 is more potent than the FDA-approved HDAC inhibitor, SAHA, as evidenced by cell growth inhibition, cytotoxicity, and better HDAC-inhibition activity. From the results of fluorogenic HDAC assay, MPT0G028 mainly targeted on class I HDACs. MPT0G028 increased the expression of acetyl-histone H3, p21, and to a less extent on acetyl-α-tubulin. Moreover, the data showed that MPT0G028 triggered apoptosis in HCT-116 cells, including Sub G1 induction and cleavage of caspase 3 and PARP. We also observed the upregulation of pro-apoptotic proteins (Bak and Bim) and the reduction of anti-apoptotic proteins (BID proform, Bcl-2, Bcl-xL, and Mcl-1). Moreover, MPT0G028 decreased the protein level of β-catenin and its upstream proteins (Akt and phospho-GSK-3β) as well as its downstream proteins (cyclin D1, c-Myc, and survivin). Finally, MPT0G028 inhibited tumor growth in a dose-dependent manner with low toxicity as evidenced by no obvious body weight loss in HCT-116 xenograft model. In conclusion, MPT0G028 inhibited HDAC activities, triggered apoptosis and down-regulated the expression of β-catenin as well as its up/down-stream proteins in CRC cancer cells. Key words: Colorectal cancer, HDAC inhibitor, apoptosis, β-catenin | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T00:14:34Z (GMT). No. of bitstreams: 1 ntu-102-R00443019-1.pdf: 5395973 bytes, checksum: 1aa9c0e5d64b9a8bea3e279cad3f3d7e (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 縮寫表 1
中文摘要 2 英文摘要 3 第一章 研究動機與目的 5 第二章 文獻回顧 6 第三章 實驗材料與方法 第一節 實驗材料 40 第二節 實驗方法 42 第四章 實驗結果 48 第五章 討論 52 第六章 結論與展望 56 參考文獻 73 | |
dc.language.iso | zh-TW | |
dc.title | 新穎HDAC抑制劑-MPT0G028在人類大腸癌細胞之抗癌機轉探討 | zh_TW |
dc.title | Anticancer activity of the novel histone deacetylase inhibitor, MPT0G028, in human colorectal cancer cells in vitro and in vivo | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 潘秀玲(Shiow-Lin Pan) | |
dc.contributor.oralexamcommittee | 黃德富(Tur-Fu Huang),顏茂雄(Mao-hsiung Yen),楊春茂(Chuen-Mao Yang) | |
dc.subject.keyword | 大腸直腸癌,HDAC抑制劑,細胞凋亡,β-catenin, | zh_TW |
dc.subject.keyword | Colorectal cancer,HDAC inhibitor,apoptosis,β-catenin, | en |
dc.relation.page | 76 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2013-07-31 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 5.27 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。